PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Average Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on PROCEPT BioRobotics, with 10 hold, three buy, two sell and one strong-buy recommendation. The average 12-month price target is $28, versus a recent share price of $21.60.
• In its latest quarter, PROCEPT reported $94.5 million in revenue, up 19.3% year over year and ahead of estimates, but its adjusted loss of $0.47 per share slightly missed expectations. The company remains unprofitable, with a negative net margin of 32.53%.
• The company faces investor securities-fraud litigation alleging it overstated demand and recurring sales through late-quarter discounts and contributed to excess customer inventory; these claims remain allegations. Separately, CEO Larry L. Wood purchased 23,900 shares for approximately $498,315.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) has earned an average rating of "Hold" from the sixteen research firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $28.00.

A number of research analysts have weighed in on the company. Citigroup lowered PROCEPT BioRobotics to a "hold" rating in a report on Thursday, July 2nd. TD Cowen cut their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a "buy" rating for the company in a research note on Wednesday, August 5th. Leerink Partners downgraded shares of PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $31.00 to $29.00 in a research note on Thursday, June 11th. William Blair downgraded shares of PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Finally, Robert W. Baird set a $20.00 price target on PROCEPT BioRobotics in a research note on Wednesday, August 5th.

PROCEPT BioRobotics Stock Up 1.6%

PROCEPT BioRobotics stock opened at $21.60 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The stock has a market capitalization of $1.24 billion, a PE ratio of -11.13 and a beta of 0.89. The business has a 50 day simple moving average of $20.36 and a 200-day simple moving average of $24.06. PROCEPT BioRobotics has a 12 month low of $16.67 and a 12 month high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). The business had revenue of $94.50 million for the quarter, compared to analysts' expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company's quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.35) EPS. On average, analysts anticipate that PROCEPT BioRobotics will post -1.67 EPS for the current fiscal year.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Several law firms, including Hagens Berman, Rosen, Kaplan Fox, Pomerantz, and others, are soliciting investors who purchased PRCT securities between February 28, 2024, and February 25, 2026. Investors have until September 22, 2026, to seek appointment as lead plaintiff. Hagens Berman class-action announcement
• Negative Sentiment: The underlying lawsuit alleges that PROCEPT misled investors about demand and recurring sales trends by using repeated late-quarter bulk discounts to encourage handpiece purchases, potentially inflating reported revenue signals. The complaint also points to weaker-than-expected unit handpiece sales and excess inventory held by customers. These are allegations, and the company’s liability has not been established. Kahn Swick & Foti securities-fraud announcement
• Negative Sentiment: The legal action creates potential costs, management distraction, and continued uncertainty around PROCEPT’s sales practices, inventory levels, and the sustainability of its growth. The concentration of similar investor-alert releases may keep attention on the lawsuit even though the announcements do not represent new operating results or a new company disclosure. Glancy Prongay Wolke securities-fraud deadline alert

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Larry L. Wood acquired 23,900 shares of PROCEPT BioRobotics stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the acquisition, the chief executive officer owned 23,900 shares in the company, valued at approximately $498,315. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Advisory Services Network LLC increased its position in PROCEPT BioRobotics by 1.3% during the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company's stock worth $1,158,000 after purchasing an additional 250 shares during the period. Osaic Holdings Inc. grew its holdings in PROCEPT BioRobotics by 20.3% during the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company's stock worth $115,000 after acquiring an additional 337 shares during the period. ProShare Advisors LLC increased its holdings in shares of PROCEPT BioRobotics by 4.7% in the 4th quarter. ProShare Advisors LLC now owns 9,726 shares of the company's stock valued at $306,000 after purchasing an additional 438 shares in the last quarter. California State Teachers Retirement System lifted its stake in shares of PROCEPT BioRobotics by 1.4% in the second quarter. California State Teachers Retirement System now owns 49,446 shares of the company's stock valued at $2,848,000 after purchasing an additional 693 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company's stock worth $29,000 after buying an additional 746 shares in the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source